Cargando…

A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies

Cardiac amyloidosis (CA), a significant condition resulting in infiltrative cardiomyopathy and heart failure with preserved ejection fraction (HFpEF), is caused by extracellular deposition of amyloid fibrils in the heart. Even though this has been known for an extended period, its prevalence in elde...

Descripción completa

Detalles Bibliográficos
Autores principales: Raval, Maharshi, Siddiq, Sajid, Sharma, Kamal, Sanghvi, Labdhi, Jain, Akhil, Patel, Sagar, Trivedi, Jaahnavee, Uttam Chandani, Kanishka, Patel, Dhriti, Desai, Rupak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995736/
https://www.ncbi.nlm.nih.gov/pubmed/36911240
http://dx.doi.org/10.12688/f1000research.130285.1
_version_ 1784902884761010176
author Raval, Maharshi
Siddiq, Sajid
Sharma, Kamal
Sanghvi, Labdhi
Jain, Akhil
Patel, Sagar
Trivedi, Jaahnavee
Uttam Chandani, Kanishka
Patel, Dhriti
Desai, Rupak
author_facet Raval, Maharshi
Siddiq, Sajid
Sharma, Kamal
Sanghvi, Labdhi
Jain, Akhil
Patel, Sagar
Trivedi, Jaahnavee
Uttam Chandani, Kanishka
Patel, Dhriti
Desai, Rupak
author_sort Raval, Maharshi
collection PubMed
description Cardiac amyloidosis (CA), a significant condition resulting in infiltrative cardiomyopathy and heart failure with preserved ejection fraction (HFpEF), is caused by extracellular deposition of amyloid fibrils in the heart. Even though this has been known for an extended period, its prevalence in elderly patients with heart failure is increasingly being recognized. Recent advances in diagnosis with non-invasive methods like technetium pyrophosphate-labeled cardiac scintigraphy (i.e., Tc-PYP scan) and treatment options with tafamidis have played a pivotal role in awareness of the burden of this disease. Management of cardiac complications like heart failure, atrial arrhythmias, conduction block, ventricular arrhythmias, coronary artery disease, and aortic stenosis is now more critical than ever. We aim to review and outline the recent advances in diagnoses of CA. We also review management strategies for cardiac complications of CA with a brief summary of disease-modifying therapies.
format Online
Article
Text
id pubmed-9995736
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-99957362023-03-10 A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies Raval, Maharshi Siddiq, Sajid Sharma, Kamal Sanghvi, Labdhi Jain, Akhil Patel, Sagar Trivedi, Jaahnavee Uttam Chandani, Kanishka Patel, Dhriti Desai, Rupak F1000Res Review Cardiac amyloidosis (CA), a significant condition resulting in infiltrative cardiomyopathy and heart failure with preserved ejection fraction (HFpEF), is caused by extracellular deposition of amyloid fibrils in the heart. Even though this has been known for an extended period, its prevalence in elderly patients with heart failure is increasingly being recognized. Recent advances in diagnosis with non-invasive methods like technetium pyrophosphate-labeled cardiac scintigraphy (i.e., Tc-PYP scan) and treatment options with tafamidis have played a pivotal role in awareness of the burden of this disease. Management of cardiac complications like heart failure, atrial arrhythmias, conduction block, ventricular arrhythmias, coronary artery disease, and aortic stenosis is now more critical than ever. We aim to review and outline the recent advances in diagnoses of CA. We also review management strategies for cardiac complications of CA with a brief summary of disease-modifying therapies. F1000 Research Limited 2023-02-20 /pmc/articles/PMC9995736/ /pubmed/36911240 http://dx.doi.org/10.12688/f1000research.130285.1 Text en Copyright: © 2023 Raval M et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Raval, Maharshi
Siddiq, Sajid
Sharma, Kamal
Sanghvi, Labdhi
Jain, Akhil
Patel, Sagar
Trivedi, Jaahnavee
Uttam Chandani, Kanishka
Patel, Dhriti
Desai, Rupak
A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies
title A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies
title_full A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies
title_fullStr A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies
title_full_unstemmed A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies
title_short A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies
title_sort review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995736/
https://www.ncbi.nlm.nih.gov/pubmed/36911240
http://dx.doi.org/10.12688/f1000research.130285.1
work_keys_str_mv AT ravalmaharshi areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT siddiqsajid areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT sharmakamal areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT sanghvilabdhi areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT jainakhil areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT patelsagar areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT trivedijaahnavee areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT uttamchandanikanishka areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT pateldhriti areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT desairupak areviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT ravalmaharshi reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT siddiqsajid reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT sharmakamal reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT sanghvilabdhi reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT jainakhil reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT patelsagar reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT trivedijaahnavee reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT uttamchandanikanishka reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT pateldhriti reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies
AT desairupak reviewofrecentadvancesinthediagnosisofcardiacamyloidosistreatmentofitscardiaccomplicationsanddiseasemodifyingtherapies